Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
Biomarkers of systemic treatment response in people with psoriasis: a scoping review.
复制标题
DOI：
10.1111/bjd.21677
复制
发表时间：
2022-10
影响因子：
10.3
通讯作者：
Smith, Catherine H.
中科院分区：
文献类型：
--
作者：
Corbett, Mark;Ramessur, Ravi;Marshall, David;Acencio, Marcio L.;Ostaszewski, Marek;Barbosa, Ines A.;Dand, Nick;Di Meglio, Paola;Haddad, Salma;Jensen, Andreas H. M.;Koopmann, Witte;Mahil, Satveer K.;Rahmatulla, Seher;Rastrick, Joe;Saklatvala, Jake;Weidinger, Stephan;Wright, Kath;Eyerich, Kilian;Barker, Jonathan N.;Ndlovu, Matladi;Conrad, Curdin;Skov, Lone;Smith, Catherine H.
通常用于治疗牛皮癣的全身治疗的反应各不相同。准确预测有效性和安全性的生物标志物将能够实现有针对性的治疗选择、改善患者的治疗结果和更具成本效益的医疗保健。进行范围界定审查，为转化研究界识别和分类银屑病全身治疗反应的候选生物标志物。对 CENTRAL、Embase、LILACS 和 MEDLINE 进行了系统检索，查找 1990 年至 2021 年 12 月期间发表的相关文章。资格标准是涉及银屑病患者（任何年龄，n≥50）的研究，报告与全身治疗反应相关的生物标志物。主要结局是系统治疗功效或安全性的任何衡量标准。数据由一名评审员提取并由另一名评审员检查；符合最低质量标准（使用控制混杂的方法）的研究被正式评估为偏倚。候选生物标志物由多利益相关方专家小组通过多数投票共识确定，并映射到相关的细胞和分子途径。在 71 项纳入的研究中（67 项研究有效性结果，8 项研究安全性结果；4 项研究两者），大多数报告的基因组或蛋白质组生物标志物与生物制剂的反应相关（48 项研究）。方法或报告的局限性经常影响对结果的解释，包括对关键协变量的控制不足、缺乏对多重测试的调整以及选择性的结果报告。我们确定了对肿瘤坏死因子抑制剂（CARD14、CDKAL1、IL1B、IL12B 和 IL17RA 基因座的变异，以及脂多糖诱导的 2 型树突状细胞中核因子 (NF)-κB 的磷酸化）和优特克单抗（HLA-C*06:02 和 IL1B 基因座的变异）有效的候选生物标志物。在没有进一步验证研究的情况下，没有足够的证据支持临床使用。研究发现候选生物标志物参与银屑病发病机制中涉及的免疫细胞串扰，最显着的是抗原呈递、辅助性 T (Th)17 细胞分化、NF-κB 正向调节和 Th17 细胞激活。这个综合目录为研究人员提供了关键资源，并揭示了所纳入研究中的各种生物标志物类型和结果。确定的候选生物标志物需要在方法学上可靠的研究中进行进一步评估，以确定潜在的临床实用性。未来的研究应旨在解决本综述中强调的常见方法学局限性，以加快临床使用生物标志物的发现和验证。通常用于治疗牛皮癣的全身治疗的反应各不相同。准确预测有效性和安全性的生物标志物将能够实现有针对性的治疗选择、改善患者的治疗结果和更具成本效益的医疗保健。 关于这个主题已有哪些已知信息？ 本综述提供了银屑病全身治疗反应的研究生物标志物的综合目录。纳入的研究中发现了多种生物标志物类型和结果，成为转化研究界的关键资源。 这项研究增加了什么？ 通常用于治疗牛皮癣的全身治疗的反应各不相同。准确预测有效性和安全性的生物标志物将能够实现有针对性的治疗选择、改善患者的治疗结果和更具成本效益的医疗保健。本综述提供了银屑病全身治疗反应的研究生物标志物的综合目录。 链接评论：A.D. Ormerod。 Br J Dermatol 2022； 187：458-459。
Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost‐effective healthcare. To perform a scoping review to identify and catalogue candidate biomarkers of systemic treatment response in psoriasis for the translational research community. A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n ≥ 50) reporting biomarkers associated with systemic treatment response. The main outcomes were any measure of systemic treatment efficacy or safety. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise and mapped to relevant cellular and molecular pathways. Of 71 included studies (67 studying effectiveness outcomes and eight safety outcomes; four studied both), most reported genomic or proteomic biomarkers associated with response to biologics (48 studies). Methodological or reporting limitations frequently compromised the interpretation of findings, including inadequate control for key covariates, lack of adjustment for multiple testing, and selective outcome reporting. We identified candidate biomarkers of efficacy to tumour necrosis factor inhibitors [variation in CARD14, CDKAL1, IL1B, IL12B and IL17RA loci, and lipopolysaccharide‐induced phosphorylation of nuclear factor (NF)‐κB in type 2 dendritic cells] and ustekinumab (HLA‐C*06:02 and variation in an IL1B locus). None were supported by sufficient evidence for clinical use without further validation studies. Candidate biomarkers were found to be involved in the immune cellular crosstalk implicated in psoriasis pathogenesis, most notably antigen presentation, T helper (Th)17 cell differentiation, positive regulation of NF‐κB, and Th17 cell activation. This comprehensive catalogue provides a key resource for researchers and reveals a diverse range of biomarker types and outcomes in the included studies. The candidate biomarkers identified require further evaluation in methodologically robust studies to establish potential clinical utility. Future studies should aim to address the common methodological limitations highlighted in this review to expedite discovery and validation of biomarkers for clinical use. Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost‐effective healthcare. What is already known about this topic? This review provides a comprehensive catalogue of investigated biomarkers of systemic treatment response in psoriasis. A diverse range of biomarker types and outcomes was found in the included studies, serving as a key resource for the translational research community. What does this study add? Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost‐effective healthcare. This review provides a comprehensive catalogue of investigated biomarkers of systemic treatment response in psoriasis. Linked Comment: A.D. Ormerod. Br J Dermatol 2022; 187:458–459.
登录
查看更多内容
影响因子：
10.3
作者：
Chiu, H. -Y.;Wang, T. -S.;Tsai, T. -F.
通讯作者：
Tsai, T. -F.
影响因子：
5.8
作者：
Liu, Yufang;Qin, Guifang;Cao, Jingjing
通讯作者：
Cao, Jingjing
影响因子：
1.6
作者：
Naldi, Luigi
通讯作者：
Naldi, Luigi
影响因子：
16.6
作者：
Andres-Ejarque R;Ale HB;Grys K;Tosi I;Solanky S;Ainali C;Catak Z;Sreeneebus H;Saklatvala J;Dand N;de Rinaldis E;Chapman A;Nestle FO;Barnes MR;Warren RB;Reynolds NJ;Griffiths CEM;Barker JN;Smith CH;Di Meglio P;PSORT Consortium
通讯作者：
PSORT Consortium
影响因子：
105.7
作者：
Parisi, Rosa;Iskandar, Ireny Y. K.;Ashcroft, Darren M.
通讯作者：
Ashcroft, Darren M.